Author

Marcos Pedrosa

LOW INCIDENCE OF HYPERBILIRUBINAEMIA EVENTS WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS

Manuel Romero-Gomez, Rui Tato Marinho, Ramon Vila, David E. Bernstein, Federico Rodriguez-Perez, Tarek Hassanein, K. Reddy, Naoky Tsai, Sandra Lovell, Jeffrey Enejosa, Yan Luo, Daniel E. Cohen, Marcos Pedrosa, Massimo Colombo

MANAGEMENT OF HAEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS

Daniel Forton, Hendrik Reesink, David E. Bernstein, Thomas Sepe, John Vierling, William King, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Yan Luo, Marcos Pedrosa, Peter Ferenci

NORMALIZATION OF LIVER-RELATED LABORATORY PARAMETERS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS AFTER TREATMENT WITH ABT-450/R/OMBITASVIR, DASABUVIR AND RIBAVIRIN

Stefan Zeuzem, Stanislas Pol, Marc Bourlière, Angeles Castro, Marina Berenguer, Sam Lee, Gregory Everson, Sandra Lovell, Marcos Pedrosa, Roger Trinh

SAFETY COMPARISON OF 12- AND 24-WEEK TREATMENTS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS: RESULTS FROM TURQUOISE-II

Heiner Wedemeyer, Xavier Forns, Antonio Craxi, Paul Kwo, Stefan Bourgeois, Michael Bennett, Stephen Ryder, Dominique Larrey, David Mutimer, Sandra Lovell, Manal Abunimeh, Marcos Pedrosa, Roger Trinh

Item 1 - 4 / 4
1